A detailed history of Profund Advisors LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 18,720 shares of RCUS stock, worth $289,036. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,720
Previous 19,737 5.15%
Holding current value
$289,036
Previous $300,000 4.67%
% of portfolio
0.01%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$13.69 - $18.01 $13,922 - $18,316
-1,017 Reduced 5.15%
18,720 $286,000
Q2 2024

Aug 13, 2024

SELL
$14.59 - $18.48 $506,170 - $641,126
-34,693 Reduced 63.74%
19,737 $300,000
Q1 2024

May 08, 2024

BUY
$14.83 - $20.18 $167,059 - $227,327
11,265 Added 26.1%
54,430 $1.03 Million
Q4 2023

Feb 14, 2024

SELL
$13.43 - $19.63 $106,177 - $155,194
-7,906 Reduced 15.48%
43,165 $824,000
Q3 2023

Nov 13, 2023

SELL
$17.62 - $23.54 $93,826 - $125,350
-5,325 Reduced 9.44%
51,071 $916,000
Q2 2023

Aug 10, 2023

SELL
$16.97 - $22.03 $362,750 - $470,913
-21,376 Reduced 27.49%
56,396 $1.15 Million
Q1 2023

May 11, 2023

BUY
$15.96 - $23.15 $1.24 Million - $1.8 Million
77,772 New
77,772 $1.42 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.11B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.